Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. For further discussion, see Item 7. The results of this trial have no impact on our submission plans. Prolia® was launched in the United States and Europe in 2010. This competition could impact the pricing and market share of our products. Such activities can offer important opportunities for differentiation. We plan to continue pursuing innovation efforts to strengthen our competitive position. The products we manufacture consist of both biologics and small molecule drugs. See Reimbursement section above. See Marketing, Distribution and Selected Marketed Products—Patents. It is being investigated in phase 3 studies for chemotherapy-induced thrombocytopenia. It is being evaluated in phase 3 as a treatment for severe asthma. We discuss the results of these surveys with our Board of Directors. From 2015 to 2019, Mr. Graham was Senior Vice President, General Counsel and Secretary. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. Similar laws exist in Oregon and Washington. Further, government regulation of payers may affect these trends. We could face audit challenges to our application of the 2017 Tax Act. We operate in a highly competitive environment. Business—Marketing, Distribution and Selected Marketed Products—Competition. Certain of the existing patents on our products have expired. For example, our clinical trials have been adversely affected by the COVID-19 pandemic.
